Description: Oxford BioDynamics Plc is a biotechnology company, which is engaged in biomarker research and development. The Company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. Its geographical segments include UK and Malaysia. Its EpiSwitch is an industrial platform for the discovery, evaluation, validation and monitoring of a class of epigenetic biomarkers known as chromosome conformation signatures (CCSs). EpiSwitch is a biomarker technology platform that facilitates pharmaceutical and biotechnology companies in their therapeutic development programs and the development of companion diagnostics. The EpiSwitch technology has validated biomarkers in a range of diseases, including Alzheimer's disease, breast cancer, ulcerative colitis and liver cancer. Its service offering includes predictive biomarkers, prognostic biomarkers, residual disease monitoring biomarkers, diagnostic biomarkers and companion diagnostic biomarkers.
Home Page: www.oxfordbiodynamics.com
OBD Technical Analysis
3140 Rowan Place
Oxford,
OX4 2WB
United Kingdom
Phone:
44 1865 518 910
Officers
| Name | Title |
|---|---|
| Dr. Jon Anthony Joseph Burrows B.Sc., M.Sc., Ph.D. | CEO & Director |
| Mr. Paul Leslie Stockdale F.C.A., M.A. | CFO & Director |
| Dr. Alexandre Akoulitchev Ma (Oxon), Ph.D. | Chief Scientific Officer & Director |
| Mr. Thomas G. Guiel B.A. | Chief Operating Officer |
| Dr. Jayne Green B.Sc., Ph.D. | Director of Operations |
| Dr. Ewan Hunter B.Sc., BSC, Ph.D., Ph.D., (KCL) | C.D.O |
| T. Demain | Company Sec. |
| Dr. Steven Tucker M.D., FACP | Group Clinical Director |
| Prof. Siamon Gordon | Clinical Director of Inflammation & Infection |
| Dr. Sandy Primrose Ph.D. | Technical Consultant |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Life Sciences Tools & Services |
| GIC Sub-Industry: | Life Sciences Tools & Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.4405 |
| Price-to-Sales TTM: | 170.0273 |
| IPO Date: | |
| Fiscal Year End: | September |
| Full Time Employees: | 44 |